Robert Parsons
Psychiatric/Mental Health · Youngstown, OHNPI 1588625081
Payments from drug & device makers
Across 1,033 payments — averaging $114.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$80K
- Alkermes, Inc.$27K
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Lundbeck LLC$1K
- plus $4K from 22 others
What the payments were for
- Consulting fees$11,44010%
- Speaking & faculty fees$72,60561%
- Travel & lodging$17,29115%
- Food & beverage$17,18014%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 161 | $79,576 |
| Alkermes, Inc. | 120 | $27,064 |
| AbbVie | 74 | $2,634 |
| Otsuka America Pharmaceutical, Inc. | 164 | $2,125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 117 | $1,644 |
| Lundbeck LLC | 134 | $1,298 |
| Teva Pharmaceuticals USA, Inc. | 46 | $705 |
| Johnson & Johnson | 37 | $655 |
| Vanda Pharmaceuticals Inc. | 47 | $591 |
| Neurocrine Biosciences, Inc. | 31 | $561 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $370 |
| Almatica Pharma LLC | 11 | $210 |
| Sunovion Pharmaceuticals Inc. | 10 | $153 |
| Axsome Therapeutics, Inc. | 7 | $146 |
| Supernus Pharmaceuticals, Inc. | 8 | $137 |
| Tris Pharma Inc | 8 | $137 |
| Corium, LLC | 8 | $135 |
| Noven Therapeutics, LLC | 7 | $133 |
| Idorsia Pharmaceuticals US Inc | 5 | $83 |
| Eisai Inc. | 4 | $69 |
| Avanir Pharmaceuticals, Inc. | 4 | $65 |
| Indivior Inc. | 3 | $54 |
| Merck | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Orexo US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$72,831
- COBENFY$64,232
- ARISTADA$33,125
- ARISTADA INITIO$1,480
- VRAYLAR$1,375
How this compares
$118,639 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $208,223 |
| Austedo XrDeutetrabenazine | 21 | $169,083 |
| AustedoDeutetrabenazine | 20 | $126,467 |
| CaplytaLumateperone Tosylate | 60 | $100,479 |
| Invega SustennaPaliperidone Palmitate | 29 | $93,101 |
| RexultiBrexpiprazole | 45 | $68,528 |
| VraylarCariprazine Hcl | 42 | $60,860 |
| TrintellixVortioxetine Hydrobromide | 105 | $50,322 |
| FetzimaLevomilnacipran Hcl | 48 | $24,522 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $18,311 |
| Chlorpromazine Hcl | 45 | $10,513 |
| QuviviqDaridorexant Hcl | 14 | $7,160 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,361 |
| Vilazodone Hcl | 38 | $4,078 |
| Fluoxetine Hcl | 149 | $3,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $705 | $295,55041 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $561 | $208,22327 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,644 | $100,47960 claims |
| Johnson & JohnsonInvega Sustenna | $655 | $93,10129 claims |
| AbbVieVraylar, Fetzima | $2,634 | $85,38290 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,125 | $68,52845 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $370 | $56,683121 claims |
| Axsome Therapeutics, Inc.Auvelity | $146 | $18,31116 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $83 | $7,16014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Youngstown
- Noah HochendonerYoungstown$34K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.